SequelSEC

Altimmune, Inc. ALT

Pharmaceutical Preparations · CIK 0001326190 · Fiscal year ends 1231

Revenue
$41.00K
Fiscal year ended 2025-12-31
Operating income
-$94.49M
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

Valuation, from the filing

Public float$326.80MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$2.51Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue7970.7×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity1.5×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
R&D / revenue162029.3%100th
FCF margin-164746.3%1th
SBC / revenue39209.8%98th
Net margin-214861.0%2th
Operating margin-230461.0%2th
Current ratio18.55x94th
CapEx / revenue26.8%88th
Revenue YoY growth105.0%83th
Long-term debt / equity0.15x24th

Altimmune, Inc. (ALT) reported revenue of $41.00K and net income of -$88.09M for the fiscal year ended 2025-12-31. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Altimmune, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Altimmune, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-31
Revenue$41.00K
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$94.49M
Net income-$88.09M
Research & development$66.43M
Weighted-average diluted sharesUnavailable
Pretax income-$88.77M
Income tax expense-$681.00K
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$28.10M
Selling & marketingUnavailable

Balance

Altimmune, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-31
Cash & equivalents$43.76M
Total assets$279.93M
Current assets$278.19M
Total liabilities$55.04M
Current liabilities$15.00M
Total equity incl. NCI$224.89M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivableUnavailable
GoodwillUnavailable
Long-term debt$34.29M
Accounts payable$2.72M

Cash flow

Altimmune, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-31
Operating cash flow-$67.54M
Capital expendituresUnavailable
Investing cash flow-$132.47M
Financing cash flow$206.84M
Net change in cash$6.83M
Stock-based compensation$16.08M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

Altimmune, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-31
Free cash flowUnavailable
Gross marginUnavailable
Operating margin-230461.0%
FCF marginUnavailable
SBC / revenue39209.8%
Current ratio18.55x
Revenue YoY growth105.0%
Net margin-214861.0%
R&D / revenue162029.3%
CapEx / revenueUnavailable
Long-term debt / equity0.15x
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ALT in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-12View SEC filing
10-Q · Filed 2026-05-13View SEC filing
10-K · Filed 2026-03-06View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-Q · Filed 2025-08-12View SEC filing
10-Q · Filed 2025-05-13View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.